Novartis AG ADR (NVS)vsPrivia Health Group Inc (PRVA)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
PRVA
Privia Health Group Inc
$20.42
+0.25%
HEALTHCARE · Cap: $2.61B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2304% more annual revenue ($56.69B vs $2.36B). NVS leads profitability with a 22.5% profit margin vs 1.2%. NVS trades at a lower P/E of 20.7x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PRVA
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for PRVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Earnings expanding 250.0% YoY
Conservative balance sheet, low leverage
Revenue surging 21.4% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
ROE of 0.0% — below average capital efficiency
1.2% margin — thin
Operating margin of 1.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PRVA
The strongest argument for PRVA centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 21.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PRVA
The primary concerns for PRVA are Return on Equity, Profit Margin, Operating Margin. A P/E of 92.8x leaves little room for execution misses. Thin 1.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a value stock while PRVA is a growth play — different risk/reward profiles.
PRVA carries more volatility with a beta of 0.88 — expect wider price swings.
PRVA is growing revenue faster at 21.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 50/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Privia Health Group Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Privia Health Group, Inc. is a population health technology and medical practice management company in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?